復星醫藥(02196.HK)法莫替丁注射液獲國家藥監局批准藥品註冊申請
復星醫藥(02196.HK)公布,控股子公司錦州奧鴻藥品股份有限公司就法莫替丁注射液的藥品註冊申請,獲國家藥品監督管理局批准。藥品劑型為注射劑,規格為2ml:20mg,註冊分類化學藥品3類。
該藥品為集團自主研發的化學藥品,是次核准適應症為用於消化性潰瘍所致消化道出血,除腫瘤及食道、胃底靜脈曲張以外的各種原因所致的胃及十二指腸黏膜糜爛出血者。
截至今年8月,集團現階段針對該藥品累計研發投入約767萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.